Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon-alpha 1b
- Development stage
- Unknown
- Lead developer
- 三元基因
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular, Intravenous, Local Injection (e.g. Paraspinal For Experimental Pain Indications)
01
Overview
Interferon-alpha 1b is a recombinant type I interferon in the interferon-alpha family, developed and used in China. It is a biologic agent with multiple biological functions, including **antiviral, antitumor, and immunomodulatory effects**. It exerts its effects by binding to the interferon alpha/beta receptor on cell surfaces, activating the JAK-STAT signaling pathway, and inducing the expression of numerous genes involved in the immune response. These actions lead to inhibition of viral replication, modulation of immune cells, and anti-proliferative effects on malignant cells. Interferon-alpha 1b has been evaluated for the treatment of viral infections (notably hepatitis B), some cancers, and investigationally for postherpetic neuralgia and other indications. It is considered a novel class of interferons with distinct rights in China and is not marketed in the US or EU[5].
- Brand names
- YunDeSu运德素
- Other names
- IFN-alpha 1bIFN-alpha1bIFN-alpha-1bIFN-α1brecombinant human interferon alpha-1b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon-alpha 1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon-alpha 1b.